The molecular events underlying prostatic tumorigenesis remain incompletely understood. The application of cytogenetic, molecular genetic and molecular cytogenetic techniques have led to the identification of consistent genetic changes. This paper will discuss these techniques, review the genetic aberrations discovered, and consider how these aberrations contribute to our knowledge of the initiation, progression, metastatic spread and resistance to hormonal therapy of prostate cancer.